Clinical Trials Logo

Filter by:
NCT ID: NCT01493284 Completed - Clinical trials for Symptomatic Aortic Stenosis

Portico TAVI Implant With Transfemoral Delivery System

Start date: December 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and the SJM TAVI Transfemoral Transcatheter delivery system in subjects with severe symptomatic aortic stenosis (AS).

NCT ID: NCT01493037 Completed - Clinical trials for ST Elevation (STEMI) Myocardial Infarction

PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention

pRAMSES
Start date: December 2011
Phase: N/A
Study type: Interventional

A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of PICSO treatment. This is a proof of concept study designed to document the safety and feasibility of the Pressure Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse system.

NCT ID: NCT01492400 Completed - Macular Edema Clinical Trials

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Start date: March 9, 2012
Phase: Phase 2
Study type: Interventional

This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).

NCT ID: NCT01492361 Completed - Clinical trials for Cardiovascular Diseases

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

REDUCE-IT
Start date: November 2011
Phase: Phase 3
Study type: Interventional

AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.

NCT ID: NCT01492101 Completed - Clinical trials for Metastatic Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

BEACON
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.

NCT ID: NCT01492088 Completed - Clinical trials for Relapsed or Refractory Hodgkin Lymphoma

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Start date: April 16, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.

NCT ID: NCT01491815 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Start date: December 14, 2012
Phase: Phase 4
Study type: Interventional

This is an international (Sweden, Finland, Norway, Denmark, Iceland and the Netherlands) trial designed to compare the safety and efficacy of active conventional therapy (ACT) and three biologic treatments in subjects with early rheumatoid arthritis (RA). The global aim of this study is to assess and compare 1. the proportion of subjects who achieve remission with ACT versus three different biologic therapies (Certolizumab-pegol, Abatacept or Tocilizumab) 2. two alternative de-escalation strategies in patients who respond to first-line therapy.

NCT ID: NCT01491711 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate

Start date: August 2013
Phase: Phase 4
Study type: Interventional

Skin cancer is the most common cancer in Caucasians, and a basal cell carcinoma (BCC) being the most common skin cancer with around 44,000 new tumours per year, and its incidence is still rising. In the past it has been a disease of the elderly patient but as a consequence of recreational sun exposure and tanning beds, more young patients develop a skin cancer as well. There are different subtypes of BCC and most subtypes are treated by surgical excision. Nowadays, non-invasive techniques as photodynamic therapy (PDT) are common practice to treat superficial BCC (sBCC). Because of these techniques treatment by surgical excision can be avoided with the possibility of complications and scar formation. Both 5-aminolevulino acid (5-ALA) and the more lipophilic methyl aminolevulinate (MAL) can be used as a precursor of the photosensitiser. These agents generate an excess of protoporphyrin IX in metabolic active cells, which are illuminated by a specific light source leading to release of reactive oxygen radicals in tissue. The result is apoptosis and necrosis of tumour cells. At the moment, two treatment protocols are used in the Netherlands: the fractionated 5-ALA 20% (Fagron) protocol according to de Haas and the MAL (Metvix, Galderma) protocol. Because MAL was first marketed and registered as a treatment option for premalignant and superficial malignancies most hospitals in the Netherlands use this topical agent. However, there is no evidence which of the 2 agents is more (cost-)effective and/ or preferred by patients. Objective: to determine which treatment is the most effective treatment in terms of prevention of treatment failure, cost saving and patients preference when comparing fractionated 5-ALA 20% PDT versus MAL PDT in 2 treatment sessions.

NCT ID: NCT01491282 Recruiting - Obesity Clinical Trials

Study of the Effect of Vagus Nerve Stimulation on Human Brown Adipose Tissue Activity

Start date: January 2011
Phase: N/A
Study type: Observational

To evaluate the effect of vagus nerve stimulation for refractory epilepsy on the activity of human brown adipose tissue.

NCT ID: NCT01491100 Completed - Multiple Sclerosis Clinical Trials

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

CogniPlus
Start date: April 30, 2012
Phase:
Study type: Observational

Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.